Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

49.16 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cardlytics, Novo Nordisk, Micron, and ModivCare and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Turnaround Tuesday - A Top 2025 Pick And A New Opportunity ↗
Novo Nordisk recently had positive news on a trial about its impact on kidney disease, the stock then gapped up, and then sold off back to major support. 
Via Talk Markets
Topics Stocks / Equities
News headline image
$100 Invested In Novo Nordisk 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Novo Nordisk Stock Slides Before Q4 Earnings: Analysts Still See 68% Upside ↗
Novo Nordisk (NVO) reports Q4 earnings with expectations of 86 cents EPS and $11.40B revenues. Stock down 29.55% YOY, 4.81% YTD. Analysts see 68% upside. 
Via Benzinga
News headline image
Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity ↗
 
Via Benzinga
News headline image
Lowey Dannenberg Notifies Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema Trial Results For Weight Loss ↗
Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors question trial protocols and transparency as Novo plans a new study. 
Via Benzinga
News headline image
Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now
Teva Pharmaceuticals is the world's largest generic drug maker with over 500 generics in its portfolio, but shares sold off on its recent earnings, buying opp? 
Via MarketBeat
News headline image
3 Magnificent Stocks to Buy and Hold Forever ↗
Via The Motley Fool
News headline image
NOVO NORDISK A/S (NYSE: NVO) INVESTOR ALERT: Investors With Large Losses in Novo Nordisk A/S Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Market Briefing For Monday, Feb. 3, 2025 ↗
As to the market, at the moment it is being reactive to tariffs, news of which of course aborted the effort at finishing January on a strong note. It's that basic. 
Via Talk Markets
Topics Commodities Stocks / Equities World Trade
News headline image
Top Picks For 2025: Skye Bioscience ↗
Skye Bioscience is developing a peripheral restricted CB1 antibody to treat obesity by restoring leptin sensitivity and increasing fat metabolism, while avoiding the CB1-induced THC/neuro side effects.... 
Via Talk Markets
Topics Stocks / Equities
News headline image
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands ↗
Via The Motley Fool
News headline image
Want $1 Million in Retirement? 2 Stocks to Buy Now and Hold for Decades. ↗
Via The Motley Fool
News headline image
NVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
Lowey Dannenberg Notifies Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
Investors should take notice of NYSE:NVO—it offers a great deal for the fundamentals it presents. ↗
Take a closer look at NOVO-NORDISK A/S-SPONS ADR , a remarkable value stock. NYSE:NVO excels in fundamentals and maintains a very reasonable valuation. 
Via Chartmill
News headline image
Billionaire Philippe Laffont Just Sold Top Artificial Intelligence Stocks Nvidia and AMD and Piled Into 2 Players Dominating Another High-Growth Billion-Dollar Industry ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Novo Nordisk (NVO) Faces Securities Class Action After Weight Loss Therapy Trial Data Disappoints, Analyst Questions Trial’s Design – Hagens Berman
From Hagens Berman Sobol Shapiro LLP
Via GlobeNewswire
News headline image
NOVO NORDISK ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders ↗
Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people. 
Via Benzinga
Topics Government
News headline image
ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVO
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
NVO INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
News headline image
5 Monster Stocks to Hold for the Next 10 Years ↗
Most Wall Street professionals obsess over short-term returns. However, patient individual investors who buy and hold leading stocks on the cusp of new growth trends could strike it rich. 
Via The Motley Fool
News headline image
Ozempic Receives FDA Approval To Treat Kidney Disease ↗
The FDA on Tuesday approves Ozempic, the weight loss drug made by Novo Nordisk, for the treatment of chronic kidney disease in patients who also have type 2 diabetes. 
Via Benzinga
News headline image
NVO Investor Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against Novo Nordisk A/S
From Robbins LLP
Via GlobeNewswire
News headline image
How Ozempic And Legal Weed Are Changing What America Eats ↗
Ozempic curbs appetites, while cannabis legalization fuels munchies. Explore their public health impacts. 
Via Benzinga
Topics Cannabis
News headline image
What Does the Future Hold for Eli Lilly?
Eli Lilly's two major GLP-1 drugs have dominated headlines, but a slate of new treatments in development—and some already available—suggest a bright future. 
Via MarketBeat
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.